Literature DB >> 20973434

An update on cancer survival.

Larry F Ellison1, Kathryn Wilkins.   

Abstract

Statistics Canada routinely produces cohort-based estimates for cancer survival; the most recent were based on cases diagnosed from 1992-2000. This report provides predicted survival estimates for cases diagnosed more recently. Using records from the Canadian Cancer Registry linked to the Canadian Vital Statistics Death Data Base, cancer- and age-specific estimates of relative survival have been calculated for 2004-2006. The five-year relative survival ratio (RSR) for all cancers combined was 62%, and ranged from 6% for pancreatic cancer to 98% for cancer of the thyroid. The RSR was typically higher at younger than older ages, with exceptions for some common cancers. From 1992-1994 to 2004-2006, the five-year RSR for a number of cancers increased--usually slightly, but in some cases, appreciably (for example, the age-standardized RSR for non-Hodgkin lymphoma rose from 51% to 63%; for leukemia, from 44% to 54%; and for liver, 9% to 17%).

Entities:  

Mesh:

Year:  2010        PMID: 20973434

Source DB:  PubMed          Journal:  Health Rep        ISSN: 0840-6529            Impact factor:   4.796


  27 in total

1.  Relative survival analysis using the Centers for Disease Control and Prevention's National Program of Cancer Registries Surveillance System Data, 2000-2007.

Authors:  Reda J Wilson; A Blythe Ryerson; Kevin Zhang; Xing Dong
Journal:  J Registry Manag       Date:  2014

2.  Do breast cancer survivors' post-surgery difficulties with recreational activities persist over time?

Authors:  Baukje Miedema; Ryan Hamilton; Sue Tatemichi; Roanne Thomas-Maclean; Thomas F Hack; Elizabeth Quinlan; Anna Towers; Andrea Tilley; Winkle Kwan
Journal:  J Cancer Surviv       Date:  2011-07-07       Impact factor: 4.442

3.  Increasing incidence in liver cancer in Canada, 1972-2006: Age-period-cohort analysis.

Authors:  Xiaohong Jiang; Sai Yi Pan; Margaret de Groh; Shiliang Liu; Howard Morrison
Journal:  J Gastrointest Oncol       Date:  2011-12

4.  Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from a Single Institute.

Authors:  Yajie Zhao; Chengfeng Wang
Journal:  J Gastrointest Surg       Date:  2019-04-03       Impact factor: 3.452

5.  Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.

Authors:  Mitsuro Kanda; Tsutomu Fujii; Hideki Takami; Masaya Suenaga; Yoshikuni Inokawa; Suguru Yamada; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Shuji Nomoto; Yasuhiro Kodera
Journal:  Surg Today       Date:  2013-10-09       Impact factor: 2.549

6.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

7.  Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort study.

Authors:  Ashley Davidson; Stephen Chia; Robert Olson; Alan Nichol; Caroline Speers; Andy J Coldman; Chris Bajdik; Ryan Woods; Scott Tyldesley
Journal:  CMAJ Open       Date:  2013-11-07

8.  A population-based study of the epidemiology of pancreatic cancer: a brief report.

Authors:  R S Raju; N Coburn; N Liu; J M Porter; S J Seung; M C Cheung; N Goyert; N B Leighl; J S Hoch; M E Trudeau; W K Evans; K N Dainty; C C Earle; N Mittmann
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

9.  Canadian trends in liver cancer: a brief clinical and epidemiologic overview.

Authors:  P De; D Dryer; M C Otterstatter; R Semenciw
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

10.  CA 19-9 and pancreatic cancer.

Authors:  Erxi Wu; Shuang Zhou; Kruttika Bhat; Qingyong Ma
Journal:  Clin Adv Hematol Oncol       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.